Use of a traditional Chinese medicine composition in preparation of a medicine for promoting recovery of functions of a human body in a recovery period of a novel coronavirus infection

Abstract

The application discloses application of a traditional Chinese medicine composition in preparation of a medicine for promoting recovery of human functions in a recovery period of novel coronavirus infection, and the traditional Chinese medicine composition contains Astragalus membranaceus, Cornus officinalis, Atractylodes macrocephala, Poria cocos, Codonopsis pilosula, Radix et Rhizoma Lycii, Salvia miltiorrhiza, Motherwort, Taxillus sutchuenensis, Pyrrosia lingua, Oldenlandia diffusa and Radix Adenophorae. For patients with olfactory and gustatory disorders in the recovery period of novel coronavirus infection, the traditional Chinese medicine composition can effectively recover the olfactory and gustatory functions. In addition, the traditional Chinese medicine composition can effectively improve the fatigue symptoms in the recovery period of novel coronavirus infection, and meanwhile, can enhance the immunity of patients in the recovery period of novel coronavirus infection. The traditional Chinese medicine composition provides a new choice for development of the medicine for promoting recovery of human functions in the recovery period of novel coronavirus infection, and has a wide application prospect.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of traditional Chinese medicine, in particular, to application of a traditional Chinese medicine composition in preparation of a medicine for promoting recovery of human body function in a novel coronavirus infection recovery period. BACKGROUND

[0002] After novel coronavirus infection, most patients recover about 10 days after treatment, but a part of patients will have a series of long-term clinical symptoms involving multiple systems and organs of the whole body after treatment, that is, they enter the novel coronavirus infection recovery period. Patients in the novel coronavirus infection recovery period not only include severe hospitalized patients, but also patients with mild or moderate symptoms or even patients who have not been hospitalized, who can also show similar symptoms. The persistent presence of multiple system symptoms and functional impairment greatly affects the long-term quality of life and daily activities of patients.

[0003] Patients in the novel coronavirus infection recovery period often have symptoms of loss of smell or taste. Loss of smell is often manifested as a decrease or loss of sensitivity to odor stimuli, in addition, a small number of patients also have symptoms such as rhinorrhea and nasal itching. Loss of taste is mainly manifested as a lack of sensitivity of the tongue to any taste stimuli, a lack of response to extreme tastes, and an inability to distinguish tastes. Due to the lack of taste stimuli, patients have reduced salivary secretion, and further have symptoms such as dry mouth and dry throat. Loss of smell and taste is often difficult to recover, which reduces the appetite of patients in the novel coronavirus infection recovery period, and even leads to malnutrition, seriously affecting the quality of life of patients.

[0004] In addition to the loss of smell and taste, patients in the novel coronavirus infection recovery period often have symptoms of fatigue. Persistent fatigue can reduce the attention, energy and vitality of patients, and affect the quality of life of patients. Studies have found that the cell typing of patients in the novel coronavirus infection recovery period is mainly characterized by a decrease in the proportion of T lymphocytes (CD4, CD8), indicating that the patient's body is still in a state of low immune function.

[0005] Some patients in the novel coronavirus infection recovery period have symptoms similar to myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS). Among the population who have persistent debilitating symptoms after acute COVID-19, about 13-45% of patients meet the case definition of ME / CFS of the National Academy of Sciences. However, although most of the symptoms of the two diseases are similar, symptoms such as decreased sense of smell and taste, skin rash and hair loss, which are very common in patients in the novel coronavirus infection recovery period, are rarely reported in ME / CFS patients (PMID: 37342500).

[0006] Due to the diverse clinical symptoms and complex course of the convalescent period of novel coronavirus infection, it is of great scientific significance and clinical value to explore specific drugs to promote the recovery of human body function in the convalescent period of novel coronavirus infection. The cost of new drug research and development is high. In recent years, the research strategy of old drugs for new use has become a hot spot in drug research and development. Qilu Yishen Decoction is derived from the clinical prescription of Professor Du Yumo of Nephrology Department. It is composed of 13 kinds of traditional Chinese medicines. Huangqi and Luancao are the monarch drugs to warm and tonify the spleen and kidney and eliminate dampness and turbidity. Baizhu, Fuling, Dangshen and Zhisu are the minister drugs to assist the monarch drugs in invigorating the spleen and warming the kidney and eliminating dampness and turbidity. Danshen and Yimucao are the auxiliary drugs to activate blood and resolve stasis. Shanzhu and Sangjisheng are the assistant drugs to tonify the kidney and produce essence. Shive and Baihuasheshecao are the drugs to clear heat and drain dampness and regulate the drugs. Huai Niuxi is the leading drug to lead all the drugs into the lower energizer. The 13 kinds of traditional Chinese medicines have synergistic effect and can warm and tonify the spleen and kidney yang deficiency, eliminate dampness and turbidity, and have the characteristics of tonifying without greasiness, warming without dryness, and the combination of cold and warm drugs, and the combination of symptoms and root causes. Qilu Yishen Tablets made from Qilu Yishen Decoction are a new type of traditional Chinese medicine in China, which is clinically used for the treatment of chronic kidney disease. At present, there is no new use of Qilu Yishen Decoction in promoting the recovery of human body function in the convalescent period of novel coronavirus infection. SUMMARY

[0007] In order to overcome the above-mentioned defects and shortcomings in the prior art, the present application provides an application of a traditional Chinese medicine composition in the preparation of a drug for promoting the recovery of human body function in the convalescent period of novel coronavirus infection.

[0008] The first object of the present application is to provide an application of a traditional Chinese medicine composition in the preparation of a drug for promoting the recovery of human body function in the convalescent period of novel coronavirus infection.

[0009] Therefore, the present application claims the following:

[0010] An application of a traditional Chinese medicine composition in the preparation of a drug for promoting the recovery of human body function in the convalescent period of novel coronavirus infection, wherein the traditional Chinese medicine composition comprises, by weight, 48-52 parts of Huangqi, 28-32 parts of Luancao, 17-21 parts of Baizhu, 17-21 parts of Fuling, 17-21 parts of Dangshen, 6-10 parts of Heishunpian, 13-17 parts of Shanzhu, 26-30 parts of Danshen, 49-53 parts of Yimucao, 23-27 parts of Sangjisheng, 17-21 parts of Shive, 40-44 parts of Baihuasheshecao and 14-18 parts of Niuxi.

[0011] Preferably, the traditional Chinese medicine composition comprises, by weight, 50 parts of Huangqi, 30 parts of Luancao, 19 parts of Baizhu, 19 parts of Fuling, 19 parts of Dangshen, 8 parts of Heishunpian, 15 parts of Shanzhu, 28 parts of Danshen, 51 parts of Yimucao, 25 parts of Sangjisheng, 19 parts of Shive, 42 parts of Baihuasheshecao and 16 parts of Niuxi.

[0012] Preferably, the promoting recovery of human body function in the recovery period of novel coronavirus infection is recovery of olfactory function of the novel coronavirus infection recovery period patient with olfactory disorder.

[0013] Preferably, the promoting recovery of human body function in the recovery period of novel coronavirus infection is recovery of taste function of the novel coronavirus infection recovery period patient with taste disorder.

[0014] Preferably, the promoting recovery of human body function in the recovery period of novel coronavirus infection is improvement of fatigue symptoms of the novel coronavirus infection recovery period patient.

[0015] Preferably, the promoting recovery of human body function in the recovery period of novel coronavirus infection is enhancement of immunity of the novel coronavirus infection recovery period patient.

[0016] More preferably, the enhancement of immunity of the novel coronavirus infection recovery period patient is reduction of levels of immunoglobulin IgA, IgM and / or IgG in the body fluid of the novel coronavirus infection recovery period patient.

[0017] More preferably, the enhancement of immunity of the novel coronavirus infection recovery period patient is reduction of levels of complement C3 and / or complement C4 in the body fluid of the novel coronavirus infection recovery period patient.

[0018] More preferably, the enhancement of immunity of the novel coronavirus infection recovery period patient is improvement of percentage of CD3 lymphocytes and / or CD4 lymphocytes in the body fluid of the novel coronavirus infection recovery period patient.

[0019] More preferably, the enhancement of immunity of the novel coronavirus infection recovery period patient is improvement of ratio of CD4 / CD8 lymphocytes in the body fluid of the novel coronavirus infection recovery period patient.

[0020] As an implementable manner, the medicine is in the form of solid, semi-solid or liquid.

[0021] As an implementable manner, the dosage form of the medicine includes but is not limited to tablets, capsules, granules, pills, powders, mixtures.

[0022] As an implementable manner, the medicine further includes a pharmaceutically acceptable excipient.

[0023] As an implementable manner, the pharmaceutically acceptable excipient includes a filler, a surfactant, a binder, an antioxidant, a preservative, a flavoring agent, a lubricant, a coating agent or a colorant.

[0024] Compared with the prior art, the present application has the following beneficial effects:

[0025] The application discloses application of a traditional Chinese medicine composition in preparation of a medicine for promoting recovery of human body functions in a recovery period of novel coronavirus infection, and the traditional Chinese medicine composition contains Astragalus membranaceus, Pyrola rotundifolia, Atractylodes macrocephala, Poria cocos, Codonopsis pilosula, black ginseng, Cornus officinalis, Salvia miltiorrhiza, Motherwort, Taxillus sutchuenensis, Pyrrosia calcicola, Oldenlandia diffusa and Radix Achyranthis Bidentatae. For patients in the recovery period of novel coronavirus infection who have olfactory and gustatory disorders, the traditional Chinese medicine composition can effectively recover the olfactory and gustatory functions of the patients. After taking the traditional Chinese medicine composition for 5-7 days, the olfactory or gustatory functions of 80-95% of the patients in the recovery period of novel coronavirus infection who have olfactory or gustatory disorders are recovered.

[0026] In addition, the traditional Chinese medicine composition can also effectively improve the fatigue symptoms of patients in the recovery period of novel coronavirus infection, and simultaneously enhance the immunity of the patients in the recovery period of novel coronavirus infection, specifically, reduce the levels of immunoglobulin IgA, IgM, IgG, complement C3 and complement C4 in the body fluid of the patients in the recovery period of novel coronavirus infection, and improve the percentage of CD3 and CD4 lymphocytes and the ratio of CD4 / CD8 lymphocytes in the body fluid of the patients in the recovery period of novel coronavirus infection. The traditional Chinese medicine composition provides a new choice for development of the medicine for promoting recovery of human body functions in the recovery period of novel coronavirus infection, and has a wide application prospect. DETAILED DESCRIPTION

[0027] The application will be further described below in combination with specific examples, but the examples do not limit the application in any form. Unless otherwise specified, the reagents, methods and devices used in the application are conventional reagents, methods and devices in the technical field.

[0028] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0029] Example 1: Preparation method of a traditional Chinese medicine composition

[0030] Take 50 parts of Astragalus membranaceus, 30 parts of Pyrola rotundifolia, 19 parts of Atractylodes macrocephala, 19 parts of Poria cocos, 19 parts of Codonopsis pilosula, 8 parts of black ginseng, 15 parts of Cornus officinalis, 25 parts of Taxillus sutchuenensis, 28 parts of Salvia miltiorrhiza, 51 parts of Motherwort, 19 parts of Pyrrosia calcicola, 42 parts of Oldenlandia diffusa and 16 parts of Radix Achyranthis Bidentatae, soak the medicinal materials in water for 30 minutes, and then decoct three times, with water added in an amount of 7 times, 5 times and 5 times respectively, and each time decocted for 30 minutes. Combine the three medicinal liquids to obtain the traditional Chinese medicine composition.

[0031] Example 2: Preparation method of a traditional Chinese medicine composition

[0032] Take 48 parts of Huangqi, 28 parts of Lianqiao, 17 parts of Baizhu, 17 parts of Fuling, 17 parts of Dangshen, 6 parts of Zhishengpi (Heishunpian), 13 parts of Shanzha, 23 parts of Sangjisheng, 26 parts of Danshen, 49 parts of Yimucao, 17 parts of Shiwve, 40 parts of Baihuasheshecao, 14 parts of Niuxi, soak the medicinal materials in water for 30 minutes, decoct three times, the amount of water is 7 times, 5 times and 5 times respectively, decoct for 30 minutes each time, combine the three medicinal liquids to obtain the traditional Chinese medicine composition.

[0033] Example 3: Preparation method of a traditional Chinese medicine composition

[0034] Take 52 parts of Huangqi, 32 parts of Lianqiao, 21 parts of Baizhu, 21 parts of Fuling, 21 parts of Dangshen, 10 parts of Zhishengpi (Heishunpian), 17 parts of Shanzha, 27 parts of Sangjisheng, 30 parts of Danshen, 53 parts of Yimucao, 21 parts of Shiwve, 44 parts of Baihuasheshecao, 18 parts of Niuxi, soak the medicinal materials in water for 30 minutes, decoct three times, the amount of water is 7 times, 5 times and 5 times respectively, decoct for 30 minutes each time, combine the three medicinal liquids to obtain the traditional Chinese medicine composition.

[0035] Example 4: Traditional Chinese medicine composition for improving fatigue symptoms and enhancing immunity in patients with new coronavirus infection in recovery period

[0036] I. Experimental method

[0037] 1. Experimental grouping

[0038] A randomized controlled trial was used to select patients with new coronavirus infection in recovery period who received rehabilitation treatment. Finally, 80 patients who met the study criteria were randomly divided into 3 experimental groups and 1 control group.

[0039] Patient inclusion criteria: patients with new coronavirus infection in recovery period; body temperature returned to normal for more than 3 days; age 18-65 years old, gender unrestricted.

[0040] Exclusion criteria: patients with mental illness, cognitive impairment and legal disability; patients with severe primary heart, liver, kidney, blood or life-threatening diseases; pregnant or lactating women; patients known to be allergic to drugs used in this trial; patients who participated in other drug clinical trials within 1 month.

[0041] 2. Administration method

[0042] The control group of patients was only given conventional treatment, and the experimental 1-3 groups of patients additionally took the traditional Chinese medicine composition prepared by examples 1-3, two doses per day, 200 mL per dose, for 4 consecutive weeks.

[0043] The conventional treatment includes home health education, drug support treatment and psychological intervention. Home health education includes: home activity suggestions, diet suggestions, personal protection suggestions. Drug support treatment refers to: for patients with hypertension, diabetes, dyslipidemia and other underlying diseases, appropriate drug treatment is given according to the specific condition of the patient. For patients with psychological dysfunction, timely psychological rehabilitation treatment is given, including mindfulness relaxation and cognitive behavioral therapy, etc.

[0044] 3. Therapeutic observation index

[0045] (1) Fatigue state evaluation

[0046] The Chalder Fatigue Scale (CFQ-11) was used to evaluate the fatigue of the two groups of patients before and after administration. The scale includes two items of somatic fatigue (questions 1-7) and psychological fatigue (questions 8-11), with question 11 being reverse scoring (i.e. 0 points for yes, 1 point for no), and other questions being forward scoring (i.e. 1 point for yes, 0 point for no). There are 11 items in total, all items are scored using a 2-level scoring method of 0-1, the total score range is 0-11, a score of ≥4 is considered to meet the standard of fatigue, and the higher the score, the more severe the fatigue.

[0047] (2) Immune function

[0048] Venous blood was drawn from the two groups of patients in the morning on an empty stomach before and after administration, and flow cytometry was used to detect the changes in peripheral T lymphocyte subsets (CD3, CD4, CD8). Blood biochemical instrument was used to detect the changes of peripheral humoral immune related indexes (IgA, IgM, IgG, complement C3, complement C4) of the two groups of patients.

[0049] (3) Changes in other clinical symptoms: record the presence or absence of clinical symptoms of the two groups of patients before and after administration (statistical items include: insomnia, anxiety, chest tightness, muscle soreness, joint pain, palpitation, indigestion, dizziness, chest pain, hand numbness, cough, shortness of breath after exercise, hair loss and other symptoms).

[0050] (4) Safety evaluation: vital signs: blood pressure, heart rate, respiratory rate, body temperature; laboratory tests: blood routine, liver function, kidney function; adverse reactions: abdominal distension, abdominal pain, diarrhea, belching, nausea, vomiting and other digestive system discomfort, skin rash, itching, local flushing and other skin allergic reactions, dizziness, headache, rapid heart rate and other discomforts.

[0051] 4. Data analysis

[0052] Prism 10 software was used for statistical analysis, and the results were analyzed by t-test for inter-group test. The data is expressed as mean ± standard deviation, and P<0.05 is considered to be of significant meaning.

[0053] II. Experimental results

[0054] The fatigue condition results are shown in Table 1. Compared with before administration, after taking the traditional Chinese medicine compositions prepared in Examples 1-3 for 2 weeks and 4 weeks, the CFQ-11 fatigue scores of the experimental groups 1-3 were significantly reduced (P<0.05); compared with the control group, after administration for 2 weeks and 4 weeks, the CFQ-11 fatigue scores of the experimental groups 1-3 were significantly reduced (P<0.05); compared with the experimental group 1 at the same time point, the CFQ-11 fatigue scores of the experimental groups 2 and 3 had no significant difference (P>0.05).

[0055] Table 1 Comparison of CFQ-11 scale scores before and after administration of patients (mean ± SD)

[0056] Group Example Before administration 2 weeks after administration 4 weeks after administration Experiment 1 group 20 8.3±2.4 6.2 ± 1.5 *# ]] 3.1 ± 0.6 *# ]] Experiment 2 group 20 8.1±2.0 6.0 ± 1.7 *# ]] 3.0 ± 0.5 *# ]] Experiment 3 group 20 8.4±2.2 6.5 ± 1.3 *# ]] 3.4 ± 0.7 *# <!-- 4 -->]]> Control group 20 8.6±2.1 8.1±1.8 6.3±1.1

[0057] Note: compared with before administration, ** P<0.01, * P<0.05; compared with the control group at the same time point, ## P<0.01, # P<0.05.

[0058] The changes in humoral immunity related indexes are shown in Table 2. Compared with before administration, after taking the traditional Chinese medicine compositions prepared in Examples 1-3 for 2 weeks and 4 weeks, the immunoglobulin IgA, IgM, IgG and complement C3, C4 levels of the experimental groups 1-3 were significantly decreased (P<0.05); compared with the control group, after administration for 2 weeks and 4 weeks, the immunoglobulin IgA, IgM, IgG and complement C3, C4 levels of the experimental groups 1-3 were significantly decreased (P<0.05); compared with the experimental group 1 at the same time point, the immunoglobulin IgA, IgM, IgG and complement C3, C4 levels of the experimental groups 2 and 3 had no significant difference (P>0.05).

[0059] Table 2 Changes in humoral immunity related indexes (mean ± SD, n=20, g / L)

[0060]

[0061] Note: compared with before administration, ** P<0.01, * P<0.05; compared with the control group at the same time point, ## P<0.01, # P<0.05.

[0062] Compared with before administration, the percentages of CD3 and CD4 and the ratio of CD4 / CD8 in the experimental groups 1-3 were significantly increased after taking the traditional Chinese medicine composition prepared in Examples 1-3 for 2 weeks and 4 weeks (P<0.05); compared with the control group, the percentages of CD3 and CD4 and the ratio of CD4 / CD8 in the experimental groups were significantly increased after administration for 2 weeks and 4 weeks (P<0.05); compared with the experimental group 1 at the same time point, the percentages of CD3 and CD4 and the ratio of CD4 / CD8 in the experimental groups 2 and 3 had no significant difference (P>0.05).

[0063] Table 3 Changes in T lymphocyte subsets before and after administration (mean ± SD, n = 20)

[0064]

[0065]

[0066] Note: compared with before administration, ** P<0.01, * P<0.05; compared with the control group at the same time point, ## P<0.01, # P<0.05.

[0067] After taking the traditional Chinese medicine composition prepared in Examples 1-3, the number of patients with symptoms of insomnia, anxiety, chest tightness, muscle soreness, joint pain, palpitation, indigestion, dizziness, chest pain, hand numbness, cough and other symptoms in the recovery period of novel coronavirus infection was significantly less than that in the control group.

[0068] During the study, the vital signs of the four groups of patients were stable, and there were no abnormalities in the blood routine, liver function and renal function of the four groups of patients before and after administration, and no traditional Chinese medicine-related adverse reactions were found.

[0069] Example 5 Traditional Chinese medicine composition for improving olfactory dysfunction in the recovery period of novel coronavirus infection

[0070] I. Experimental method

[0071] Using the method of randomized controlled trial, 40 patients with olfactory dysfunction in the recovery period of novel coronavirus infection who received rehabilitation treatment were randomly divided into an experimental group and a control group, 20 cases in each group. The control group was only given conventional treatment, and the experimental group additionally took the traditional Chinese medicine composition prepared in Example 1 on the basis of conventional treatment, two doses per day, 200 mL per dose. The conventional treatment was the same as that in Example 4, including home health education, drug support treatment and psychological intervention.

[0072] The olfactory function was tested using the sniffin stick test. The olfactory function evaluation criteria were as follows: 48–31 points: normal olfactory function; 30–16 points: decreased olfactory function; ≤15 points: loss of olfactory function. Drug efficacy rate (%) = number of people scoring 48–31 points / total number of people. Data were analyzed using the χ² method. 2 The test showed that P < 0.05 was considered statistically significant.

[0073] II. Experimental Results

[0074] The results are shown in Table 4. On the first day after taking the traditional Chinese medicine composition prepared in Example 1, 25% of the patients recovering from olfactory dysfunction due to COVID-19 infection experienced a recovery of their sense of smell; after 5 days, 80% of the patients recovered from olfactory dysfunction due to COVID-19 infection experienced a recovery of their sense of smell; and after 7 days, 95% of the patients recovered from olfactory dysfunction due to COVID-19 infection experienced a recovery of their sense of smell. This indicates that the traditional Chinese medicine composition prepared in Example 1 has a very strong restorative effect on the olfactory function of patients recovering from olfactory dysfunction due to COVID-19 infection.

[0075] Table 4. Recovery of olfactory sense before and after drug administration (unit: person)

[0076]

[0077]

[0078] Note: Compared with the control group at the same time point. * P<0.05, ** P<0.01.

[0079] The traditional Chinese medicine compositions prepared in Examples 2 and 3 have similar effects to those prepared in Example 1 in improving olfactory dysfunction during the recovery period of novel coronavirus infection.

[0080] Example 6: Traditional Chinese medicine composition improves taste disorder during the recovery period of novel coronavirus infection.

[0081] I. Experimental Methods

[0082] A randomized controlled trial was conducted, enrolling 40 recovered COVID-19 patients with taste disorders undergoing rehabilitation treatment. They were randomly divided into an experimental group and a control group, with 20 patients in each group. The control group received only routine treatment, while the experimental group received the traditional Chinese medicine composition prepared in Example 1 in addition to routine treatment, twice daily (200 mL each time). Routine treatment was the same as in Example 4, including home health education, drug support therapy, and psychological intervention.

[0083] The taste function detection method is the Chinese version of the chemotherapy-induced taste alternation scale (CiTAS, total score 90 points, total score ≤18 points is no taste change, total score >18 points is taste change, and the higher the score, the more serious the taste change).

[0084] The taste function evaluation standard of the experiment is as follows: ≤18 points: normal taste function; 19-54 points: decreased taste function; 55-90 points: loss of taste function. The data was analyzed by χ2test, and P<0.05 was considered to have significant meaning. 2

[0085] II. Experimental results

[0086] The results are shown in Table 5. After taking the traditional Chinese medicine composition prepared in Example 1 for the first day, 25% of the patients with taste disorder in the recovery period of novel coronavirus infection felt recovery. After taking for 5 days, 80% of the patients with taste disorder in the recovery period of novel coronavirus infection felt recovery. After taking for 7 days, 95% of the patients with taste disorder in the recovery period of novel coronavirus infection felt recovery. This shows that the traditional Chinese medicine composition prepared in Example 1 has very strong recovery ability for the taste function of patients with taste disorder in the recovery period of novel coronavirus infection.

[0087] Table 5 Taste recovery of patients before and after administration (unit: person)

[0088]

[0089] Note: Compared with the control group at the same time point, * P<0.05, ** P<0.01.

[0090] The traditional Chinese medicine compositions prepared in Examples 2 and 3 have similar effects to the traditional Chinese medicine composition prepared in Example 1 in improving taste disorder caused by the recovery period of novel coronavirus infection.

[0091] The above examples are the preferred embodiments of the present application, but the embodiments of the present application are not limited by the above examples, and any changes, modifications, substitutions, combinations, simplifications made without departing from the spirit and principles of the present application are equivalent replacement methods and are included in the protection scope of the present application.​

Claims

1. The application of a traditional Chinese medicine composition in the preparation of a drug that promotes the recovery of human functional functions during the recovery period of novel coronavirus infection, characterized in that, By weight, the traditional Chinese medicine composition comprises 48-52 parts of Astragalus membranaceus, 28-32 parts of Pyrola rotundifolia, 17-21 parts of Atractylodes macrocephala, 17-21 parts of Poria cocos, 17-21 parts of Codonopsis pilosula, 6-10 parts of Aconitum carmichaelii, 13-17 parts of Cornus officinalis, 26-30 parts of Salvia miltiorrhiza, 49-53 parts of Leonurus japonicus, 23-27 parts of Taxillus chinensis, 17-21 parts of Pyrrosia lingua, 40-44 parts of Hedyotis diffusa, and 14-18 parts of Achyranthes bidentata. The aforementioned promotion of human functional recovery during the recovery period of novel coronavirus infection refers to the restoration of olfactory function in patients recovering from novel coronavirus infection who have olfactory dysfunction. The term "promoting the recovery of human function during the recovery period of COVID-19 infection" refers to restoring the taste function of patients recovering from COVID-19 infection who have taste disorders.

2. The application according to claim 1, characterized in that, By weight, the traditional Chinese medicine composition comprises 50 parts of Astragalus membranaceus, 30 parts of Pyrola rotundifolia, 19 parts of Atractylodes macrocephala, 19 parts of Poria cocos, 19 parts of Codonopsis pilosula, 8 parts of Aconitum carmichaelii, 15 parts of Cornus officinalis, 28 parts of Salvia miltiorrhiza, 51 parts of Leonurus japonicus, 25 parts of Taxillus chinensis, 19 parts of Pyrrosia lingua, 42 parts of Hedyotis diffusa, and 16 parts of Achyranthes bidentata.

3. The application according to claim 1, characterized in that, The drug is in solid, semi-solid, or liquid form.

4. The application according to claim 1, characterized in that, The dosage forms of the drug include, but are not limited to, tablets, capsules, granules, pills, powders, and mixtures.

5. The application according to claim 1, characterized in that, The drug also includes pharmaceutically acceptable excipients.

6. The application according to claim 5, characterized in that, Pharmaceutically acceptable excipients include fillers, surfactants, binders, antioxidants, preservatives, flavoring agents, lubricants, coating agents, or colorants.

Images